News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Covidien plc (COV) Nellcor Pulse Oximetry Portfolio Gets 510(k) Clearance for Motion Claim



5/20/2013 7:18:52 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Covidien Receives FDA 510(k) Clearance for Nellcor™ Pulse Oximetry Motion Claims

BOULDER, Colo.--(BUSINESS WIRE)-- Covidien, a leading global provider of healthcare products and recognized innovator in patient monitoring and respiratory care devices, today announced that its Nellcor™ pulse oximetry portfolio, which is used to measure arterial oxygen saturation, has received U.S. Food and Drug Administration (FDA) 510(k) clearance for motion claims. This makes Covidien the first company to receive FDA clearance for a motion-tolerant bedside pulse oximeter portfolio that is also compliant with ISO 80601-2-61 (International Organization for Standardization standards for pulse oximetry).

Devices covered by the action include:

Nellcor Bedside SpO2 Patient Monitoring System

Nellcor Bedside Respiratory Patient Monitoring System

NellcorN-600x Pulse Oximetry Monitoring System

Pulse oximeters provide early warning of dangerous respiratory complications, enabling clinicians to detect and address life-threatening events sooner. Nellcor devices rely on cardiac-based signals to provide a more accurate reading that is closely tied to the patient’s physiology. This drives consistent performance during various challenging conditions, such as patient motion, noise and low perfusion, which can impede the assessment of patient respiratory status.

Motion-tolerant pulse oximetry is critical for ensuring patient safety because patient movement can thwart accurate readings and delay diagnosis of serious respiratory compromise.

“For more than 30 years, clinicians have trusted Nellcor pulse oximetry to monitor their patients,” said Robert J. White, President, Respiratory and Monitoring Solutions, Covidien. “The FDA’s recent clearance of motion-tolerance claims should now give clinicians added comfort that they’re providing the highest standard of patient care.”

Covidien offers comprehensive pulse oximetry training through its new Professional Affairs and Clinical Education Online Platform to support the safe and effective use of motion-tolerant pulse oximeters. For customers, Covidien further offers in-service programs, in-house continuing education programs and field-based technical training tools.

The Nellcor Bedside SpO2 Patient Monitoring System, Bedside Respiratory Patient Monitoring System, and N-600x Pulse Oximetry Monitoring System are indicated for prescription-use only for the continuous non-invasive monitoring of functional oxygen saturation of arterial hemoglobin (SpO2) and pulse rate. They are intended for neonatal, pediatric, and adult patients, and for well or poorly perfused patients in hospitals, hospital-type facilities, intra-hospital transport and home environments.

ABOUT COVIDIEN

Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading product lines in three segments: Medical Devices, Pharmaceuticals and Medical Supplies. With 2012 revenue of $11.9 billion, Covidien has 43,000 employees worldwide in 70 countries, and its products are sold in over 140 countries. Please visit www.covidien.com to learn more about our business.

Contact:

R&MS Communications

Rhonda Luniak, 303-305-2263

Vice President

rhonda.luniak@covidien.com

or

Covidien

Bruce Farmer, 508-452-4372

Vice President

Public Relations

bruce.farmer@covidien.com

or

Coleman Lannum, CFA, 508-452-4343

Vice President

Investor Relations

cole.lannum@covidien.com

or

Todd Carpenter, 508-452-4363

Senior Director

Investor Relations

todd.carpenter@covidien.com



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES